Abstract 296P
Background
Despite the knowledge that HPV is responsible for high-grade CIN and cervical cancer, little is known about the use of therapeutic vaccines as treatment considering most studies are still in early stages. We aimed to synthesize and critically evaluate the evidence from clinical trials on the safety, efficacy, and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade CIN associated with HPV.
Methods
A systematic review of clinical trials adhering to the PRISMA 2020 statement was undertaken in MEDLINE/PubMed, Embase, CENTRAL Cochrane, Web-of-Science, Scopus, and LILACS, with no data or language restriction. Primary endpoint related to the safety, efficacy, and immunogenicity of these vaccines were assessed by analyzing the adverse/toxic effects associated with the therapeutic vaccine administration; via histopathological regression of the lesion and/or regression of the lesion size and by viral clearance; and through the immunological response of individuals who received treatment compared to those who did not or before and after receiving the vaccine, respectively.
Results
A total of 1,184 studies were identified, and 16 met all criteria. Overall, the therapeutic vaccines were heterogeneous regarding their formulation, dose, intervention protocol and routes of administration making meta-analysis unfeasible. In most studies (n=15), the vaccines were safe and well tolerated, with clinical efficacy with regards to lesions and histopathological regression or viral clearance. In addition, 11 studies showed favorable immunological responses against HPV, and seven studies showed a positive correlation between immunogenicity and clinical response, indicating promising results that should be further investigated.
Conclusions
Therapeutic vaccines, although urgently needed for avoid progression of CIN 2/3 patients, still present sparse data, requiring greater investments in well-designed phase III RCT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract